| • |
September 2011 – Construction of new API facility:
We initiated work on a new facility designed for seeking approval from international regulatory agencies.
---------------------------------------------------------------------------------------------------------------------------------------------------------------------
|
| • |
June 2011 – New PhD hires in the R&D team:
Dr. Ajay Kulkarni and Dr. Urs joined the Resonance R&D team to add to our strength in developing new products.
---------------------------------------------------------------------------------------------------------------------------------------------------------------------
|
| • |
October 2010 – New director on the board:
Dr. Mohan Kallyanpur joined Resonance as a Director on the board. Dr.Kallyanpur completed his Ph.D. from UDCT (now IICT), Mumbai, and ran his own company, Kallin Industries, makers of metal catalysts and complexes.
---------------------------------------------------------------------------------------------------------------------------------------------------------------------
|
| • |
March
2010 - DMF filing in the US:
DMFs for Buprenorphine HCl and Oxybuynin
Chloride were filed with the US FDA. Resonance
also has a COS for Oxybutynin Chloride from
EDQM.
---------------------------------------------------------------------------------------------------------------------------------------------------------------------
|
| • |
March
2010 - New product offering:
Glycopyrrolate was added
to list of products offered by Resonance.
For a full list of products refer to the
product list.
---------------------------------------------------------------------------------------------------------------------------------------------------------------------
|
| • |
February
2010 - Marketing partnership in Japan:
Resonance signed an agreement with Toray
International and LSG corporation who will
represent Resonance's services in the Japanese
market for a specific time period.
---------------------------------------------------------------------------------------------------------------------------------------------------------------------
|
| • |
December
2010 - New building complete:
Innovation centre building was completed
and commissioned at end of 2009.
--------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| • |
November
2009 - Audit by European customer:
Our quality assurance system was evaluated
for the compliance with ICH Q7 GMP guidance
for the manufacture of Oxybutynin Chloride
(Resonance has COS for the product from
EDQM). Resonance cleared the audit with
some findings.
--------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| • |
July
2009 - Approval for Oxybutynin Chloride:
Resonance's facility in India was approved
for supply of Oxybutynin Chloride by one
of our North American clients. Resonance
also has a COS registered with European
authorities for more than 5 years now.
--------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| • |
Apr
2009 - Opening of the wholly owned subsidiary
in the US:
We opened our US office on April 2, 2009
led by Tushar Gore PhD. The office is located
in Parsippany, New
Jersey and we are looking to
establish a client base in the US and strengthen
the existing base in Europe with efforts
led from this office. Tushar Gore joins
us after several years in pharmaceutical
and chemicals marketing with global companies
such as Novo Nordisk, Sun Chemical and McKinsey
& Company.
--------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| • |
Feb
2009 - Oxybutynin Chloride audit:
Our facilities in India were audited to
evaluate us as a supplier for Oxybutynin
Chloride for a major generic manufacturer.
The initial observations from the report
based on ICH Q7 guidelines were all complied
with and a final review is scheduled in
a few weeks after which Resonance will be
a qualified supplier of Oxybutynin Chloride.
---------------------------------------------------------------------------------------------------------------------------------------------------------------------
|
| • |
Jan
2009 - Innovation centre Phase I:
We started construction of phase I of the
innovation centre. It is scheduled for completion
in June and the innovation centre is planned
for accommodating R&D activities. With
growing emphasis on Research and Development
activities, we have plans for further growth
of the innovation centre in additional phases.
---------------------------------------------------------------------------------------------------------------------------------------------------------------------
|
